100 项与 Neogenesis Drug Discovery, Inc. 相关的临床结果
0 项与 Neogenesis Drug Discovery, Inc. 相关的专利（医药）
Abstracts of Papers, 221st ACS National Meeting, San Diego, CA, United States, April 1-5, 2001
Addressing genomics with combinatorial chemistry: Mixture-based solution phase libraries
作者: Rosner, Kristin E. ; Makara, Gergely ; Curran, Patrick ; Shipps, Gerald W. Jr.
To address the opportunities of genomics we have developed a versatile, expansive combinatorial chem. platform that we term NeoMorph.- The chem. uses both solution & solid phase strategies to create defined, mass-encoded mixtures of diverse, medicinally relevant small mols. that are screened against proteins of interest.
Abstracts of Papers, 221st ACS National Meeting, San Diego, CA, United States, April 1-5, 2001
On validating 3-D diversity methods: Introducing total pharmacophore diversity
作者: Makara, Gergely ; Wintner, Edward
Validation of pharmacophore derived metrics for quantifying mol. diversity usually involves comparison of 2D and 3D techniques.Such studies have often made the rather surprising and counterintuitive conclusion: 2D fingerprints elucidate exptl. data more reliably than 3D methods.This presentation details several pitfalls that should be avoided in constructing sets of mols. to be used in diversity validation.Mols. erroneously expected to be similar can have a major impact on the observed performance of diversity methods and are compared by 2D Unity and Total Pharmacophore Diversity (ToPD) fingerprints.ToPD, a new distance-based 3D method is also demonstrated to consistently and significantly outperform 2D binary fingerprints in different validation tests.The ToPD algorithm can be used for rapid evaluation of diversity in large screening libraries or generation of focused libraries as well as ligand-based virtual screening.
100 项与 Neogenesis Drug Discovery, Inc. 相关的药物交易
100 项与 Neogenesis Drug Discovery, Inc. 相关的转化医学
